trending Market Intelligence /marketintelligence/en/news-insights/trending/NfAZMC0XD-2o0C1PFq6SSg2 content esgSubNav
In This List

Myovant secures up to $140M financing to develop uterine fibroid drug

Blog

Insight Weekly: Banks brace for recession; Europe PE deal values soar; US solar imports rebound

Blog

Banking Essentials Newsletter: December 7th Edition

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes


Myovant secures up to $140M financing to develop uterine fibroid drug

Myovant Sciences Ltd. secured up to $140 million financing through two deals to fund ongoing development of its lead compound relugolix in uterine fibroids, endometriosis and prostate cancer.

The deal with NovaQuest Capital Management comprises a note purchase commitment of up to $60 million and share purchase of up to $40 million.

The agreement with Hercules Capital Inc. provides Myovant with an additional debt financing of up to $40 million.

Takeda Pharmaceutical Co. Ltd. had granted Myovant an exclusive, worldwide license to develop and market relugolix except in Japan and some Asian countries where it retains exclusive rights.

"The financings with NovaQuest and Hercules provide us with flexible access to capital, allowing us to continue the broad phase 3 development of relugolix in three indications," said Frank Karbe, Myovant's chief financial officer.